Spironolactone in Diabetic Nephropathy
Spironolactone in Diabetic Nephropathy
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.
Inclusion Criteria:
Exclusion Criteria: